New pivotal trial needed for Vion's leukaemia drug Onrigin
05 January 2010
Malini Guha
A new Phase III trial of
Vion Pharmaceuticals' lead oncology drug candidate Onrigin (laromustine; formerly cloretazine) in acute myeloid leukaemia (AML) will be needed after the US FDA told the company that an ongoing, independently sponsored Phase III trial would not suffice for the chemotherapy drug's...
Please Login to read the full article.